.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L02B_HormoneAntagonistsAndRelatedAgents.L02BB06_Darolutamide.Darolutamide .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L02B_HormoneAntagonistsAndRelatedAgents.L02BB06_Darolutamide.Darolutamide| name: | Darolutamide |
| ATC code: | L02BB06 | route: | oral |
| n-compartments | 2 |
Darolutamide is a nonsteroidal androgen receptor antagonist used to treat non-metastatic castration-resistant prostate cancer. It is an approved oral medication and is currently used in clinical settings.
Pharmacokinetic parameters reported for adult male patients with non-metastatic castration-resistant prostate cancer following oral administration of darolutamide 600 mg twice daily under fed condition.
Leblanc, K, et al., & Emmenegger, U (2024). Drug Interactions between Androgen Receptor Axis-Targeted Therapies and Antithrombotic Therapies in Prostate Cancer: Delphi Consensus. Cancers 16(19) –. DOI:10.3390/cancers16193336 PUBMED:https://pubmed.ncbi.nlm.nih.gov/39409956